{"filing":{"accession_number":"0000950103-26-008465","cik":"0001771910","ticker":"ADCT","company_name":"ADC Therapeutics SA","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"dp247928_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008465/dp247928_8k.htm"},"events":[{"id":7066,"run_id":6200,"accession_number":"0000950103-26-008465","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"ADC Therapeutics announced positive topline data from the Phase 3 LOTIS-5 confirmatory trial of ZYNLONTA plus rituximab in relapsed/refractory DLBCL, meeting the primary endpoint of progression-free survival (HR=0.73, p=0.008) with improved overall response and complete response rates versus R-GemOx, supporting a planned supplemental BLA submission.","company_name":"ADC Therapeutics SA","ticker":"ADCT","filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":[{"id":3838,"accession_number":"0000950103-26-008465","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.75,"reasoning":"Item 7.01 is a Regulation FD disclosure that references exhibits (press release and presentation) related to events described in Item 8.01, but the Item 7.01 text itself contains only boilerplate safe-harbor language and does not disclose the substantive event. Without access to Item 8.01 or the exhibits, the specific event type cannot be determined. The Item 7.01 disclosure itself is procedural and non-material; materiality depends on what Item 8.01 actually describes.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:15:47.172164+00:00","company_name":"","ticker":null,"filing_date":""},{"id":3839,"accession_number":"0000950103-26-008465","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"ADC Therapeutics announced topline data from the Phase 3 LOTIS-5 confirmatory trial of ZYNLONTA plus rituximab in r/r DLBCL, meeting the primary endpoint of PFS with statistical significance (HR=0.73, p=0.008) and demonstrating improved ORR (58.1% vs 45.2%) and CR rates (39.5% vs 26.7%) versus R-GemOx. While this is a positive clinical trial result, it does not fit neatly into \"earnings_release\" (which typically refers to financial results) nor any other specific category; the disclosure centers on clinical efficacy and safety data supporting a planned sBLA submission, making it a material clinical/regulatory milestone that warrants \"other_material\" classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:15:47.172164+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3838,"accession_number":"0000950103-26-008465","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.75,"reasoning":"Item 7.01 is a Regulation FD disclosure that references exhibits (press release and presentation) related to events described in Item 8.01, but the Item 7.01 text itself contains only boilerplate safe-harbor language and does not disclose the substantive event. Without access to Item 8.01 or the exhibits, the specific event type cannot be determined. The Item 7.01 disclosure itself is procedural and non-material; materiality depends on what Item 8.01 actually describes.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:15:47.172164+00:00","company_name":"ADC Therapeutics SA","ticker":"ADCT","filing_date":"2026-06-03"},{"id":3839,"accession_number":"0000950103-26-008465","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"ADC Therapeutics announced topline data from the Phase 3 LOTIS-5 confirmatory trial of ZYNLONTA plus rituximab in r/r DLBCL, meeting the primary endpoint of PFS with statistical significance (HR=0.73, p=0.008) and demonstrating improved ORR (58.1% vs 45.2%) and CR rates (39.5% vs 26.7%) versus R-GemOx. While this is a positive clinical trial result, it does not fit neatly into \"earnings_release\" (which typically refers to financial results) nor any other specific category; the disclosure centers on clinical efficacy and safety data supporting a planned sBLA submission, making it a material clinical/regulatory milestone that warrants \"other_material\" classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:15:47.172164+00:00","company_name":"ADC Therapeutics SA","ticker":"ADCT","filing_date":"2026-06-03"}]}